Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

[1]  G. D'Haens,et al.  Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment. , 2015, Journal of Crohn's & colitis.

[2]  J. Barkin,et al.  Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[4]  R. Gearry,et al.  Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission , 2015, Inflammatory bowel diseases.

[5]  R. Eliakim,et al.  Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  P. Rutgeerts,et al.  Factors associated with short- and long-term outcomes of therapy for Crohn's disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  G. Greenberg,et al.  The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease , 2014, Gut.

[8]  G. D'Haens,et al.  A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease: Recommendations for Clinical Trial Design , 2014, Inflammatory bowel diseases.

[9]  U. Kopylov,et al.  Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease , 2014, Alimentary pharmacology & therapeutics.

[10]  G. D'Haens,et al.  A Systematic Review of the Measurement of Endoscopic Healing in Ulcerative Colitis Clinical Trials: Recommendations and Implications for Future Research , 2014, Inflammatory bowel diseases.

[11]  S. Brand,et al.  Rate and Predictors of Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Anti-TNF-Alpha Antibodies , 2014, PloS one.

[12]  P. Rutgeerts,et al.  Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial , 2014, Gut.

[13]  L. Peyrin-Biroulet,et al.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  U. Kopylov,et al.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab , 2013, Gut.

[15]  W. Sandborn,et al.  Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  R. Eliakim,et al.  Clinical utility of antihuman lambda chain‐based enzyme‐linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti‐infliximab antibodies , 2012, Inflammatory bowel diseases.

[17]  A. Griffiths,et al.  Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. , 2012, Journal of Crohn's & colitis.

[18]  M. Färkkilä,et al.  Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease , 2012, Scandinavian journal of gastroenterology.

[19]  G. Van Assche,et al.  Therapeutic Drug Monitoring of Biologics for Inflammatory Bowel Disease , 2012, Inflammatory bowel diseases.

[20]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[21]  U. Kopylov,et al.  The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful , 2010, Gut.

[22]  Stefan Schreiber,et al.  Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[24]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[25]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[26]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[27]  M. Silverberg,et al.  Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[29]  M. Schwartz,et al.  Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis , 2005, Gut.

[30]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.